Inclusion Criteria:

- Pathologically proven diagnosis of HPV-positive squamous cell carcinoma of the
oropharynx, hypopharynx, or larynx. HPV-positivity will be defined as tumors that are
p16-positive by immunohistochemistry.

- Clinical stage III or IV disease; Note: Patients with M1 tumors are not eligible.

- Appropriate stage for protocol entry, including no distant metastases, based upon
minimum diagnostic workup

- Zubrod Performance Status 0-1

- Age > 18

- Adequate bone marrow function

- Adequate hepatic function

- Adequate renal function

- Pregnancy test within 4 weeks prior to registration for women of childbearing
potential

- Women of childbearing potential and male participants must agree to use a medically
effective means of birth control throughout their participation in the treatment
phase of the study (until at least 60 days following the last study treatment)

- Patient must sign study specific informed consent prior to study entry.

Exclusion Criteria:

- Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free
for a minimum of 3 years;

- Patients with simultaneous primaries or bilateral tumors are excluded.

- Patients who present with a cervical lymph node metastasis of unknown primary origin;

- Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a
different cancer is allowable;

- Prior radiotherapy that would result in overlap of radiation therapy fields;

- Primary site of tumor of oral cavity, nasopharynx, nasal cavity, paranasal sinuses,
or salivary glands;

- Recurrent head and neck cancer;

- Severe, active co-morbidity

- Pregnant or lactating women or women of childbearing potential and men who are
sexually active and not willing/able to use medically acceptable forms of
contraception; this exclusion is necessary because the treatment involved in this
study may be significantly teratogenic.

- Prior allergic reaction to the study drug(s) involved in this protocol.